AliquantumRx Inc. Granted Type B Pre-IND Meeting with U.S. Food and Drug Administration for Cethromycin-HCl Malaria Program
AliquantumRx Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the Company a Type B pre-Investigational New Drug (pre-IND) meeting to discuss the development of cethromycin hydrochloride (Cethromycin-HCl) for the treatment of liver-stage malaria. The FDA meeting is scheduled for March 10, 2026 and follows the Agency’s acknowledgment of AliquantumRx’s pre-IND submission and the opening […]